Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
South Korea’s Edenlux set for US debut of eye-strain wellness device

From TechCrunch

By Kate Park

January 27, 2026

South Korea’s Edenlux set for US debut of eye-strain wellness device

South Korea’s Edenlux set for US debut of eye-strain wellness device

People around the world now spend hours a day on their smartphones. On average, daily smartphone use exceeds three hours, and for many adults, total screen time climbs to six hours or more, according to research. This constant close-up screen exposure has been linked to a growing list of eye-health issues, including dry and irritated eyes, eye fatigue, blurred vision, headaches, and the worsening of nearsightedness, per reports.

Edenlux, a South Korea-headquartered startup, has developed technology to address eye and ear health issues caused by screen-heavy digital lifestyles.

The company’s mission is personal. Edenlux founder and CEO Sungyong Park knows firsthand what it feels like to lose control of your eyesight. While serving as a military physician, Park received a muscle relaxant injection for severe neck stiffness. It triggered a rare side effect: temporary paralysis of the eye muscles responsible for focusing. Doctors told him there was little to do but wait.

Park didn’t wait. He imported specialized ophthalmic equipment and began retraining his eye muscles himself. Over time, his vision gradually returned. That experience reshaped his understanding of eye health, leading Park, a medical doctor turned entrepreneur, to develop technology to help people protect and restore their vision in a screen-heavy world.

Now, Edenlux is preparing to launch its second wellness device, Eyeary, a daily visual recovery tool aimed at the U.S. market, with a planned Indiegogo launch around the end of March. Unlike medical devices, Edenlux’s products fall under the FDA’s wellness category, allowing them to be described for vision training and general eye health. (The company opted to launch on Indiegogo rather than seek investor funding, Park said, citing sufficient cash reserves to support operations for several years.)

The company’s first product, Otus, launched in 2022 in South Korea, Singapore, Japan, and Taiwan. The bulky, VR-style device uses lenses to contract and relax the ciliary muscle. Otus has generated $10 million in cumulative revenue, and Edenlux says Eyeary is designed to be faster and easier to use.

“With Otus, users typically took about 12 months to reduce their dependence on reading glasses. Eyeary could shorten that to around six months,” Park claimed.

Image Credits:Edenlux

Eyeary is also a design leap, he added. It looks like normal glasses, is lighter and more comfortable, and the lens system includes 144 focal points, allowing for finer focus adjustments and more precise eye-muscle training. (Otus has five diopter focal points.) The device pairs with a mobile app via Bluetooth, collecting usage data and feeding it to Edenlux’s servers. The company analyzes datasets across age, gender, and vision profiles, using AI to predict improvement timelines and customize training programs.

Prolonged screen time can overwork the ciliary muscle, which controls the lens inside the eye. “When people are young, the muscle is strong enough to focus,” Park said. “But constant smartphone use keeps it contracted, and over time, it can weaken, leading to fatigue and vision problems.”

Edenlux has developed a suite of products targeting specific eye conditions, including Otus and Eyeary for visual recovery, Tearmore for dry eye, Lux-S for strabismus, Lumia for myopia prevention, and Heary for auditory recovery. Tearmore, Lux-S, Lumia, and Heary are expected to roll out in Asia, Park said.

Park sees companies like Oura Ring as peers. Both collect human data and provide insights via software, on a subscription model. But while Oura focuses on heart rate and sleep, Edenlux targets vision and hearing health.

Its target customers include all individuals who regularly use smartphones and earphones. “We aim to address the root causes of eye and hearing problems from digital device overuse,” Park said.

Edenlux raised $39 million in its Series A round in 2020 and $60 million in Series B funding in 2022. The company recently established a U.S. subsidiary in Dallas, Texas, where its devices will undergo final assembly.

While Edenlux currently develops and manufactures in-house, it’s exploring partnerships with major tech firms like Apple or Samsung, aiming to integrate its vision-protecting technology with smartphones.

Combining firsthand insight, advanced science, and hardware devices, Edenlux believes that eye health in the digital age is more than a wellness trend — it’s an emerging area in consumer technology.

View original article on techcrunch.com

Most Recent

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

The potential deal highlights a growing trend of complex, multi-stage funding rounds that mask true entry prices.

Jul 17, 2026

Similar Posts

XP Health grabs $32M to bring employees more affordable vision care

XP Health grabs $32M to bring employees more affordable vision care

Antonio Moraes, the grandson of a late prominent Brazilian billionaire, was never interested in joining the family-owned conglomerate of construction companies and a bank. Shortly after graduating from college, he founded one of Brazil’s first impact funds, which invested primarily in companies that made healthcare more accessible and affordable. But while attending Stanford University, where Moraes received a master’s in business administration and healthcare policy, he realized that instead o

Sep 12, 2024

Omi, a competitor to Friend, wants to boost your productivity using AI and a ‘brain interface’

Omi, a competitor to Friend, wants to boost your productivity using AI and a ‘brain interface’

San Francisco startup Based Hardware announced during the Consumer Electronics Show in Las Vegas this week the launch of a new AI wearable, Omi, to boost productivity. The device can be worn as a necklace where Omi’s AI assistant can be activated by saying “Hey Omi.” The startup also claims Omi can be attached to the side of your head, using medical tape, using a “brain interface” to understand when you’re talking to it. The startup’s founder, Nik Shevchenko, started marketing this device on Ki

Jan 8, 2025

Eyebot gets $20M Series A to expand eye care access

Eyebot gets $20M Series A to expand eye care access

This vision care startup secures $20M Series A for 90-second prescription kiosk.

Aug 26, 2025

Sam Altman’s World unveils a mobile verification device

Sam Altman’s World unveils a mobile verification device

Tools for Humanity, the startup behind the World human verification project, unveiled a mobile verification device and expanded to the US.

Apr 30, 2025

Most Recent

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

Inference startup Infinity raises $15M from Touring Capital, OpenAI and Anthropic researchers

AI infrastructure company Infinity announced Monday a $15 million raise at a $100 million valuation from investors including Touring Capital, Principal VC, and researchers from companies such as OpenAI and Anthropic.

Jul 20, 2026

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

StrictlyVC returns to New York City September 10 to celebrate a huge year for the city’s startup community

For the first time since 2024, StrictlyVC is coming back to New York City — and we're bringing the kind of access you’d expect from an under-wraps event to the whole startup, VC, and dealmaking community.

Jul 20, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open-weight AI models for coding.

Jul 17, 2026

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

The potential deal highlights a growing trend of complex, multi-stage funding rounds that mask true entry prices.

Jul 17, 2026

Similar Posts

XP Health grabs $32M to bring employees more affordable vision care

XP Health grabs $32M to bring employees more affordable vision care

Antonio Moraes, the grandson of a late prominent Brazilian billionaire, was never interested in joining the family-owned conglomerate of construction companies and a bank. Shortly after graduating from college, he founded one of Brazil’s first impact funds, which invested primarily in companies that made healthcare more accessible and affordable. But while attending Stanford University, where Moraes received a master’s in business administration and healthcare policy, he realized that instead o

Sep 12, 2024

Omi, a competitor to Friend, wants to boost your productivity using AI and a ‘brain interface’

Omi, a competitor to Friend, wants to boost your productivity using AI and a ‘brain interface’

San Francisco startup Based Hardware announced during the Consumer Electronics Show in Las Vegas this week the launch of a new AI wearable, Omi, to boost productivity. The device can be worn as a necklace where Omi’s AI assistant can be activated by saying “Hey Omi.” The startup also claims Omi can be attached to the side of your head, using medical tape, using a “brain interface” to understand when you’re talking to it. The startup’s founder, Nik Shevchenko, started marketing this device on Ki

Jan 8, 2025

Eyebot gets $20M Series A to expand eye care access

Eyebot gets $20M Series A to expand eye care access

This vision care startup secures $20M Series A for 90-second prescription kiosk.

Aug 26, 2025

Sam Altman’s World unveils a mobile verification device

Sam Altman’s World unveils a mobile verification device

Tools for Humanity, the startup behind the World human verification project, unveiled a mobile verification device and expanded to the US.

Apr 30, 2025